Fungal Endocarditis: A Successful Case with Medical Therapy Alone
Endocardite Fúngica: Um Caso de Sucesso da Terapêutica Médica Isolada
DOI:
https://doi.org/10.60591/crspmi.237Keywords:
Antifungal Agents/therapeutic use, Candida, Endocarditis, Bacterial/drug therapyAbstract
Fungal endocarditis is a rare and potentially fatal condition,
usually caused by Candida and Aspergillus spp. There is a
higher incidence in immunosuppressed patients, patients with previous endocarditis, prosthetic valves or intracardiac devices. Antifungal therapy and surgical approaches are essential as curative intention and to avoid embolic phenomenon. Success cases are rare with medical therapy alone.
We present an 80-years-old male patient with a pacemaker
and prosthetic aortic valve, previously treated for bacterial endocarditis (without valvular intervention, but with
pacemaker replacement), who was diagnosed with fungal
endocarditis due to Candida metapsilosis. Although caspofungin and voriconazole were started there was persistent candidemia, leading to the replacement of antifungal, namely liposomal amphotericin B and flucytosine. Chronic suppression with itraconazole followed. The patient was submitted for electrode replacement, but valve intervention was not performed. During the hospital stay, multiple complications occurred but he was discharged with good evolution and no recurrence on follow-up.
This case raises the question about the role of valvular intervention on patients whose medical therapy alone is sufficient and could be considered for curative intention for fungal endocarditis.
Downloads
References
Jamil Y, Akinleye A, Mirzaei M, Lempel M, Farhat K, Pan S. Candida endocarditis: Update on management considerations. World J Cardiol. 2023;15):469-78. doi: 10.4330/wjc.v15.i10.469.
Rivoisy C, Vena A, Schaeffer L, Charlier C, Fontanet A, Delahaye F, et al. Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis-The ESCAPE Study. Clin Infect Dis. 2018;66:825-32. doi: 10.1093/cid/cix913.
2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). Eur Heart J.2023;44:3948–4042. doi: 10.1093/eurheartj/ehad193.
Kauffman MD. Candida endocarditis and suppurative thrombophlebitis. UpToDate. [accessed 5 February 2022] Available at: https://www.uptodate. com/contents/candida-endocarditis-and-suppurative-thrombophlebitis
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-50. doi: 10.1093/cid/civ933.
Yang Q, Liu Z, Wang Y, Xie J, Zhang K, Dong Y, et al. In vitro synergistic antifungal activities of caspofungin in combination with fluconazole or voriconazole against Candida species determined by the Etest method. Int J Infect Dis. 2022;122:982-90. doi: 10.1016/j.ijid.2022.07.056.
Wang A, Fosbøl EL. Current recommendations and uncertainties for surgical treatment of infective endocarditis: a comparison of American and European cardiovascular guidelines. Eur Heart J. 2022;43:1617-25. doi: 10.1093/eurheartj/ehab898.
Sahra S, Javed A, Jahangir A, Thind SK. Pharmacological options for Candida albicans Endocarditis at the roadblock with irrecoverable prosthetics and drug interactions: a case report and review of literature. BMC Infect Dis. 2023;23:304. doi: 10.1186/s12879-023-08267-z.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Jéssica Abreu, Daniela Mateus, Ema Leal, Ana Raquel Garrote, Fernando Maltez
This work is licensed under a Creative Commons Attribution 4.0 International License.